<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975349</url>
  </required_header>
  <id_info>
    <org_study_id>MS200527-0086</org_study_id>
    <secondary_id>2016-001448-21</secondary_id>
    <nct_id>NCT02975349</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this protocol is to find out about the safety and effectiveness of M2951 in
      patients with relapsing multiple sclerosis. Patients will be placed into 1 of 3 groups to
      receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the patients on placebo
      will be given M2951.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">January 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Gadolinium (Gd)-Enhancing T1 Lesions at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Gadolinium (Gd)-Enhancing T1 Lesions at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Gadolinium (Gd)-Enhancing T1 Lesions at Week 20</measure>
    <time_frame>Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Gadolinium (Gd)-Enhancing T1 Lesions at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Week 24 and 48</time_frame>
    <description>A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. This relapse must be accompanied by new clinical signs (that is changes in the neurological examination or an increase in Expanded Disability Status Scale score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects who Remain Qualified Relapse-Free</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Week 24 and 48</time_frame>
    <description>The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS) in half-point increments and should be administered in person by a neurologist trained in its use. The EDSS score will be calculated after neurologic testing and examination of the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk); Cerebellar (coordination); Brain stem (speech and swallowing); Sensory (touch and pain); Bowel and bladder functions; Visual; Mental; Other (includes any other neurological findings due to MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Abnormalities in Laboratory Safety Parameters, Vital Signs and Electrocardiograms (ECGs)</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Concentrations of Immunoglobulin (Ig) Levels</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 16, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Numbers of B Cells</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 24, 48 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Immunoglobulin (Ig) Levels</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 16, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in B Cells</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 24, 48 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of Gd+ T1 lesions at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of new Gd+ T1 Lesions</measure>
    <time_frame>Weeks 12, 16, 20, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean per-Scan Number of Gd+ T1 Lesions</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of new or Enlarging T2 Lesions</measure>
    <time_frame>Weeks 12, 16, 20, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Volume of Gd+ T1 Lesions</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Volume of T2 Lesions</measure>
    <time_frame>Week 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>M2951 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2951 Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2951 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/M2951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tecfidera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951</intervention_name>
    <description>M2951 low dose will be administered for 48 weeks</description>
    <arm_group_label>M2951 Low dose</arm_group_label>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951</intervention_name>
    <description>M2951 mid dose will be administered for 48 weeks</description>
    <arm_group_label>M2951 Mid dose</arm_group_label>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951</intervention_name>
    <description>M2951 high dose will be administered for 48 weeks</description>
    <arm_group_label>M2951 High dose</arm_group_label>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered for 24 weeks</description>
    <arm_group_label>Placebo/M2951</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecfidera</intervention_name>
    <description>Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (47 weeks)</description>
    <arm_group_label>Tecfidera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951</intervention_name>
    <description>Following Placebo for 24 weeks, M2951 low dose will be administered for 24 weeks</description>
    <arm_group_label>Placebo/M2951</arm_group_label>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of relapsing multiple sclerosis (may include subjects with
             Secondary Progressive Multiple Sclerosis (SPMS) with superimposed relapses provided
             they meet the other criteria) in accordance with revised McDonald criteria for MS and
             Lublin and Reingold

          -  Male or female aged 18 to 65 years

          -  One or more documented relapses within the 2 years before Screening with either: a)
             One relapse which occurred within the last year prior to randomization or b) the
             presence of at least 1 Gd+ T1 lesion within 6 months prior to randomization would make
             the patient eligible.

          -  Expanded Disability Status Scale score of 0 to 6 at Baseline

          -  Women of childbearing potential must use a supplementary barrier method together with
             a highly effective method of contraception (according to International Council for
             Harmonisation [ICH] guidance M3[R2]) for 4 weeks prior to randomization, throughout
             the trial, and for 90 days after the last dose of IMP.

          -  Signed and dated informed consent (subject must be able to understand the informed
             consent) indicating that the subject has been informed of all the pertinent aspects of
             the trial prior to enrolment and will comply with the requirements of the protocol.

        Exclusion Criteria:

          -  Progressive MS

          -  Disease duration &gt; 15 years in subjects with EDSS of 2 or less

          -  Use of the following, as determined in the protocol ; rituximab, ocrelizumab,
             mitoxantrone, or lymphocyte-depleting therapies, lymphocyte trafficking blockers (eg,
             natalizumab, fingolimod), intravenous (IV) immunoglobulins (Ig), plasmapheresis,
             immunosuppressive treatments, B-interferons or glatiramer acetate, Systemic
             glucocorticoids, teriflunomide

          -  Exposure to Tecfidera within 6 months prior to randomization

          -  Any allergy, contraindication, or inability to tolerate Tecfidera

          -  Treatment with dalfampridine (fampridine, Ampyra) unless on a stable dose for ≥ 30
             days prior to randomization

          -  Inability to comply with MRI scanning

          -  Immunologic disorder other than MS, with the exception of secondary well-controlled
             diabetes or thyroid disorder, or any other condition requiring oral, IV,
             intramuscular, or intra-articular corticosteroid therapy

          -  Vaccination with live or live-attenuated virus vaccine within 1 month prior to
             Screening

          -  Severe drug allergy or history of anaphylaxis, or allergy to the IMP or any of its
             incipients

          -  Active, clinically significant viral, bacterial, or fungal infection, or any major
             episode of infection requiring hospitalization or treatment with parenteral
             anti-infectives within 4 weeks of Screening, or completion of oral anti-infectives
             within 2 weeks before or during Screening, or a history of recurrent infections (ie, 3
             or more of the same type of infection in a 12-month rolling period). Vaginal
             candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the
             Investigator to be sufficiently controlled would not be exclusionary.

          -  History of or positive testing for human immunodeficiency virus (HIV), hepatitis C
             (HCV) antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg)
             (+) and/or hepatitis B core total, and/or immunoglobulin M (IgM) antibody (+) at
             Screening.

          -  The subject: • Has a history of or current diagnosis of active tuberculosis (TB) or •
             Is currently undergoing treatment for latent TB infection (LTBI) or • Has an untreated
             LTBI or • Has a positive QuantiFERON®-TB test at Screening.

          -  Indeterminate QuantiFERON®

          -  Subjects with current household contacts with active TB will also be excluded

          -  History of splenectomy or any major surgery within 2 months prior to Screening

          -  History of myocardial infarction or cerebrovascular event as per the protocol

          -  History of attempted suicide within 6 months prior to Screening or a positive response
             to items 4 or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS)

          -  An episode of major depression within the last 6 months prior to Screening

          -  On anticoagulation, fish oil supplements, or antiplatelet therapy other than daily
             aspirin for cardioprotection and treatment of Tecfidera induced flushing

          -  History of cancer, except adequately treated basal cell or squamous cell carcinoma of
             the skin

          -  Breastfeeding/lactating or pregnant women

          -  Participation in any investigational drug trial within 1 month or 5 half-lives of the
             investigational drug, whichever is longest, prior to Screening

          -  Subjects currently receiving (or unable to stop using prior to receiving the first
             dose of IMP) medications or herbal supplements known to be potent inhibitors of
             cytochrome P450 3A (CYP3A)

          -  History of or current alcohol or substance abuse

          -  Clinically significant abnormality on electrocardiogram or screening chest X-ray

          -  Clinically significant laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1142</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>41529</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-654</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-605</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saransk</city>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzice</city>
        <zip>31000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97404</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dubnica nad Vahom</city>
        <zip>01841</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M2951</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <keyword>Bruton's Tyrosine Kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

